Clinical Trials Logo

Lung Cancer, Small Cell clinical trials

View clinical trials related to Lung Cancer, Small Cell.

Filter by:

NCT ID: NCT01037023 Completed - Clinical trials for Lung Cancer, Small Cell

Regulatory Hycamtin(Oral) PMS

Hycamtin PMS
Start date: October 2010
Phase: N/A
Study type: Observational

Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of Topotecan administered in Korean patients according to the prescribing information

NCT ID: NCT00997061 Completed - Clinical trials for Lung Cancer, Small Cell

SCOT Registry: Small Cell Lung Cancer Treatment and Outcome

SCOT
Start date: November 2009
Phase: N/A
Study type: Observational

The registry is an international, multicenter, observational registry of newly diagnosed patients with SCLC. Data will be entered into an electronic CRF (eCRF) via Internet access. Treatment plan remains the responsibility of the patient's physician and data collected in this registry will reflect a "real world" approach of the diagnosis and treatment of patients with SCLC. Approximately 60 centres in 13 countries will take part in this registry. It is expected that about 500 patients will be recruited during a period of 6 to 9 months according to the feasibility.

NCT ID: NCT00698516 Completed - Clinical trials for Lung Cancer, Small Cell

Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer

Start date: July 2008
Phase: Phase 2
Study type: Interventional

Combination of Hycamtin (topotecan) and Avastin (bevacizumab) could allow killing of both endothelial and neoplastic cells. We postulate that addition of bevacizumab to topotecan will increase delivery of topotecan to tumor cells and may enhance activity of topotecan in patients with previously treated small cell lung cancer and improve progression free survival.

NCT ID: NCT00320359 Completed - Clinical trials for Lung Cancer, Small Cell

Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer

Start date: August 2002
Phase: Phase 3
Study type: Interventional

Evaluation of intravenous Topotecan + Cisplatin as a potential new standard of care in 1st line Small Cell Lung Cancer

NCT ID: NCT00316186 Completed - Clinical trials for Lung Cancer, Small Cell

First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin

Start date: June 2005
Phase: Phase 2
Study type: Interventional

This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with extensive disease small cell lung cancer.

NCT ID: NCT00276276 Completed - Clinical trials for Lung Cancer, Small Cell

Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer

Start date: November 2000
Phase: Phase 3
Study type: Interventional

The purpose of this study is to find out if giving oral HYCAMTIN to patients with relapsed small cell lung cancer benefits them. The study will compare how long patients live when they are given therapy to make them feel better (active symptom control) to the length of time patients live when they are also receiving oral HYCAMTIN.

NCT ID: NCT00259935 Completed - Clinical trials for Lung Cancer, Small Cell

A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors

Start date: October 4, 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the bioequivalence of the new oral capsule formulation to the currently used oral capsule formulation of topotecan.

NCT ID: NCT00046111 Completed - Clinical trials for Lung Cancer, Small Cell

A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors

Start date: September 2001
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare two capsules of topotecan made by slightly different methods. This will be done by giving the drug made by the two different methods to patients orally and testing blood levels.

NCT ID: NCT00043862 Completed - Clinical trials for Small Cell Lung Cancer

The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)

(SCLC)
Start date: August 2002
Phase: Phase 2
Study type: Interventional

This study will gather information on the effectiveness and safety of a treatment program for small cell lung cancer (SCLC) that uses an FDA approved chemotherapy combination, radiation therapy, and an oral investigational drug that may enhance the effects of radiation therapy. Study patients will receive two additional courses of the standard chemotherapy combination after completing radiation therapy.